

AUTOANTIBODIES IN RELATIVES OF CELIAC DISEASE PATIENTS: a follow-up of 6-10 years

Flávia Raphaela NASS¹, Lorete Maria KOTZE², Renato M. NISIHARA¹,
Iara Tabora de MESSIAS-REASON¹ and Shirley R. da Rosa UTIYAMA¹

ABSTRACT – *Context* - Autoimmune diseases are 3 to 10 times more frequently in patients with celiac disease and their relatives than in the general population. *Objective* - To investigate a broad spectrum of autoantibodies in celiac disease relatives from Southern Brazil, in a serological follow-up of 6-10 years, aiming to associate with other autoimmune diseases, degree of parentage, demographic and clinical data. *Methods* - Serum samples of 233 relatives were analyzed in two different phases: n = 186 in phase I (1997-2000) and n = 138 (being 91 = follow-up group and 47 = newly tested) in phase II (2006-2007). As controls, 100 unrelated individuals were evaluated. Autoantibodies to smooth muscle, mitochondrial, liver-kidney microsomes, parietal cell and thyroid microsomes were tested by indirect immunofluorescence. *Results* - A significant increase of autoantibodies, in both phases, was observed in the relatives when compared to the non-relatives ($P = 0.0064$), specifically to anti-thyroid microsomes and anti-parietal cell. In both phases, the female/male proportion of autoantibodies was of 4:1 to 3:1 ($P < 0.041$). The frequency of autoantibodies amongst 1st and 2nd degree relatives was 11.8% and 9.68% in phase I and 4% and 6.67% in phase II. *Conclusion* - Celiac disease relatives presented other autoantibodies and serological screening is a useful instrument for identifying autoimmune diseases along the years.

HEADINGS – Autoantibodies. Celiac disease. Autoimmune diseases. Family.

INTRODUCTION

Celiac disease (CD) is a life-long inflammatory autoimmune disease (AID) of the gastrointestinal tract affecting genetically susceptible individuals⁽¹²⁾. This enteropathy shows a well-known familiar predisposition and a prevalence of 16% among first-degree relatives^(1, 6). The risk is even greater in families with affected siblings carrying the human leukocyte antigen (HLA)-DQ2. Multiple cases in the same family are not rare and the risk of CD in second degree relatives is still significant^(11, 19). Evidence for a familial risk in CD has been accumulated from many sources, including biopsy and serological studies in families with known CD, HLA-genotyping studies, genome-wide expression and linkage studies^(14, 18).

Several AID are more prevalent among CD patients and their close relatives compared to the general population⁽²¹⁾. The coexistence of CD with other AID reinforces the involvement of common immune mechanisms and genetic factors in the pathophysiology of these disorders⁽¹⁰⁾. It is possible that chronic lymphocyte stimulation in the intestine of CD patients could result in increased autoantibody pro-

duction and therefore, stimulate the development of other AID. The most frequently reported conditions associated with CD are type 1 diabetes mellitus and autoimmune thyroiditis^(4, 11).

Considering that the delay in the diagnosis of CD can be associated to complications such as osteoporosis, anemia, infertility, malignancy, and more recently related to other AID⁽¹⁵⁾, the serological screening for autoantibodies (AAB) in relatives of celiac patients represents an important instrument for early detection of these diseases in these individuals. In this study, a broad spectrum of AAB was investigated in relatives of celiacs from southern Brazil, in a serological follow-up of 6-10 years, aiming to associate the data with occurrence of other AID, the degree of parentage, as well as demographic and clinical data of the individuals.

METHODS

The present study was approved by the local Ethics in Research Committee and written informed consent was obtained from all subjects prior to inclusion. A total of 333 individuals from Southern Brazil were included in the study. Table 1 displays demographic

Declared conflict of interest of all authors: none.

Financial support: none.

¹ Laboratory of Immunopathology, Clinical Hospital, Federal University of Paraná; ² Gastroenterology Service, Cajuru Hospital, Catholic University of Paraná, Curitiba, PR, Brazil. Correspondence: Prof. Shirley Ramos da Rosa Utiyama - Rua Padre Camargo, 280 - 80060-240 - Curitiba, PR, Brazil. E-mail: shirley@ufpr.br

TABLE 1. Demographic data of the relatives of celiac disease patients and control group

Groups	Number	Sex*	Age mean (years)
Group I – Relatives Phase I	186	108F 78M	33.68 (2-79)
Group II – Relatives Phase II			
II-A Follow-up	91	55F 36M	40.64 (10-82)
II-B newly tested relatives	47	25F 22M	24.85 (2-83)
Group III – Non relatives	100	63F 37M	33.05 (2-78)

*F=Females; M=Males

characteristics of these individuals.

Serum samples of 233 relatives (100♂, 133♀; 2-83 years) were analyzed, being 186 collected in phase I of the study (years 1997 to 2000) and 138 in phase II (years 2006 to 2007). Amongst the last one, 91 relatives were recovery from the phase I, and constitute the follow-up group; while 47 were relatives not evaluated in phase I (newly tested relatives). As control group, we studied 100 unrelated volunteers from the same geographical area, which reported no familial CD cases.

AAB to smooth muscle (SMA), mitochondrial (AMA), liver-kidney micrososome (LKM), parietal cell (PCA) and thyroid micrososome (ATM) were tested by indirect immunofluorescence (IFI), as previously described^(7, 20), using FITC polyclonal anti-human globulin conjugate (Dako, Denmark). The substrate used in the tests were cryostatic tissue sections of mouse stomach (SMA, PCA), liver (LKM) and kidney (AMA, LKM), and human thyroid (ATM). The sample was considered positive if fluorescence was seen at dilution of 1:40 to SMA, 1:10 to ATM, and 1:20 to all the other AAB. All positive samples were tittered up to the end point. Positive and negative controls were used for each bath.

All positive serum for ATM was tested for anti-peroxidase antibody (anti-TPO) by quimioluminescence (kit DPC - Diagnostic Products Corporation, Los Angeles, CA, USA).

The data were compiled in frequency and contingency tables and statistical analyses were performed with Epi-Info, using Chi squared, Fisher and Proportion tests when indicated. The significance level was set at 0.05.

RESULTS

Significant increase of AAB was observed in relatives (10.3%; 24/233) compared to the non-relatives (1%; 1/100; $P = 0.0064$), being raised and constant so in phase I (10.75%; 20/186) as in phase II of research (8.7%; 12/138). Amongst the evaluated AAB, an increased frequency for the anti-ATM (6.45%; 12/186; $P \leq 0.0050$ and 5.8%; 8/138; $P \leq 0.0117$) and anti-PCA (3.76%; 7/186; $P \leq 0.0117$ and 3.62%; 5/138; $P \leq 0.0635$) was detected in the two phases, respectively. AMA and anti-LKM were not detected. SMA was positive in two relatives in phase I (1.08%; 2/186) and in one subject in the control group (Table 2).

The female/male proportion of AAB was of 4:1 (16♂; 4♀; $P < 0.0001$) to 3:1 (9♂; 3♀; $P = 0.041$) in each phase. The frequency of AAB in 1st and 2nd degree relatives was 11.8% (19/161) and 4% (1/25) in phase I and 9.68% (9/93) and 6.67% (3/45) in phase II, without significant difference in both. Among different groups of relatives, it was observed increased and constant frequency of positive AAB in siblings

TABLE 2. Frequency of autoantibodies in relatives of celiac and non-relatives

Autoantibodies	Phase I	Phase II		Non-relatives (n=100)	P* Relatives phase I x Non relatives	P* Relatives phase II x Non relatives	P* Relatives phase I x Relatives phase II
	(n = 186)	Follow-up (n = 91)	Newly tested (n = 47)				
	n(%)						
ATM	12 (6.45)	6 (6.59)	2 (4.26)		0.0050	0.0117	NS
PCA	7 (3.76)	3 (3.30)	2 (4.26)	0 (0)	0.0473	0.0635	NS
SMA	2 (1.08)	0 (0)	0 (0)	1 (1)	NS	NS	NS
LKM	0 (0)	0 (0)	0 (0)	0 (0)	-	-	-
AMA	0 (0)	0 (0)	0 (0)	0 (0)	-	-	-
TOTAL	20 (10.75)	8 (8.79)	4 (8.51)	1 (1)	0.0055	0.0220	NS

ATM = anti-thyroid micrososome
 PCA = anti-parietal cell
 SMA = anti-smooth muscle
 LKM = anti-liver-kidney micrososome
 AMA = anti-mitochondrial
 NS = non significant
 Fisher
 Chi squared




FIGURE 1. Positivity of autoantibodies in relatives of phases I and II in relation to parentage

in both phases (9.43%; 6.25%, respectively) (Figure 1). No statistical difference was reached between AAB distribution by age, with trend to the significance ($P = 0.083$) in relatives older than 60 years compared to younger individuals in phase II (Figure 2).

The serological follow-up in 91 relatives showed positivity of 7.69% to AAB in phase I, being 2.2% (2/91) to anti-ATM, 4.4% (4/91) to anti-PCA and 1.1% (1/91) to anti-SMA. In a second occasion, after 6-10 years, the total positivity to AAB in the same ones was 8.79% (8/91), with 6.59% (6/91) to anti-ATM and 3.3% (3/91) to anti-PCA, with one relative positive concomitantly to these both antibodies in phase II. After 6-10 years, 12.09% (11/91) of the family members reevaluated showed changes in their serological profile, or remained positive for the same AAB. At this, amongst the seven positive relatives in first testing, four remained positive (three to anti-PCA; one to anti-ATM) and three became negative, whereas four previously negative individuals became positive to anti-ATM and one relative positive to anti-PCA since phase I demonstrated seroconversion for anti-ATM either ($P = NS$). Until moment, clinical diagnosis of auto-immune gastritis was confirmed in one followed-up relative.

DISCUSSION

Even though untreated celiac patients, as well as their relatives, present high prevalence of AAB, it has been not yet clarified if CD is an inflammatory disease with secondary auto-immune reactions, or if it is a primary AID induced by known environmental factors. The present study shows an increased prevalence of AAB in relatives of celiac patients, which was significantly higher in relation to non-relatives ($P = 0.0064$; 10.3% and 1% respectively). These data are in concordance with previous reports⁽¹⁰⁾.

This is a pioneer follow-up for AAB in relatives of celiac patients, and the percentage of individuals recovered during 6-10 years was relevant (48.9%; 91/186) compared to previous




FIGURE 2. Positivity to autoantibodies in relatives of phases I and II in relation to age

studies, where the maximum of recovery samples has been 30.3% (40/132)⁽⁵⁾.

Our findings suggest that one time testing is insufficient to identify all AAB positive individuals, and reinforce the need to re-evaluate family members of celiac patients who have been negative on a first serological screening. In addition, a persistent risk of developing AAB was seen in adults and children in both, first and second degree relatives. These data suggest that CD relatives should be screened not only for CD but also for other AID, even in the absence of symptoms.

Although the association of thyroid's AID and CD has been shown to be frequent, the reports on thyroid's AID in CD relatives are scarce. In both phases of this study a high prevalence to anti-ATM in relatives ($P = 0.0050$; $P = 0.0117$), followed for anti-PCA ($P = 0.0473$; $P = 0.0635$) was observed in CD relatives when compared with the control group. Ansaldi et al.⁽²⁾ showed that 26% of Italian CD patients had positive autoimmune thyroid serology compared to 10% in the control subjects. Ventura et al.⁽²⁴⁾ demonstrated high titers of serum TPO antibodies present in 14.4% of CD patients from Italy. Similar results for parietal cell auto-antibodies were obtained by Utiyama et al.⁽¹⁰⁾ in a Brazilian study that found 3.6% of positivity in CD patients and 3.4% in first degree relatives.

The serological follow-up of 6-10 years in 91 relatives showed that AAB profile is dynamic, being important to perform more than one screening. This finding is corroborated by the fact that four previously negative relatives have become positive for anti-ATM in phase II and three relatives remained positive for anti-PCA in the both phases. At present, the clinical-laboratorial evaluation of positive relatives for ATM suggested sub-clinical forms of the disease, requiring a criterious follow-up, considering that celiac relatives when in use of gluten can present thyroid disfunction throughout the time⁽²²⁾.

The concurrently occurrence of CD and pernicious anemia and/or atrophic gastritis is rare⁽²⁰⁾. However, in this study,

one female 52 years old, that was amongst the five relatives positive to anti-PCA in phase II (Table 2), had clinical and endoscopic diagnosis of auto-immune gastritis, while the others relatives still await for the results.

A highly significant positivity for AAB was seen in the women when compared to males in both phases ($P < 0.0001$; $P = 0.041$, respectively). These results corroborate with the higher predisposition of female including celiac relatives to the development of different AID^(8, 9).

The positivity of AAB between relatives > 60 years (17.65%) demonstrated a trend to the significance ($P = 0.083$) in relation to other individuals, suggesting that the persistent consumption of gluten can represent a trigger to these positivity in genetically susceptible individuals, such as celiac relatives. Although CD occurs at any age and with a great variety of manifestations, there is a marked increase in the incidence rates of CD among adults > 60 years⁽¹⁶⁾. It is important to systematically include serological screening tests for CD and other AID in the evaluation of these susceptible

adults. Atypical manifestations and low suspicion can delay diagnosis even during years^(13, 17).

The findings of parentage were interesting. The value of this serological study between siblings of celiac patients was emphasized, since AAB positivity were similar after 6-10 years, in contrast to the frequency of AAB in the other relatives. This issue highlights the increased risk to the development of other AID in these individuals (Figure 1), similarly to the higher risk to develop CD^(3, 14).

CONCLUSION

In conclusion, our data suggest that first and second degree relatives of celiac patients are a group of individuals that shows positive serological test results for AID, hence, this population need to be evaluated for the presence of AAB more than once, irrespective to the presence of symptoms. Serological screening is a useful instrument for identifying these affections along the years.

Nass FR, Kotze LM, Nisihara RM, Messias-Reason IT, Utiyama SRR. Autoanticorpos em familiares de pacientes celíacos: seguimento por 6 a 10 anos.

Arq Gastroenterol. 2012;49(3):199-203.

RESUMO – *Contexto* - Doenças autoimunes são 3 a 10 vezes mais frequentes em pacientes com doença celíaca e em seus familiares que na população em geral. *Objetivos* - Realizar amplo perfil de autoanticorpos em familiares de celíacos do sul do Brasil, em seguimento sorológico de 6-10 anos, visando associá-lo com outras doenças autoimunes, grau de parentesco, dados demográficos e clínicos desses indivíduos. *Métodos* - Foram analisadas amostras de 233 familiares em duas etapas diferentes: n = 186 na etapa I (1997-2000) e n = 138 (91 recoleta e 47 novos familiares testados) na etapa II (2006-2007). Como controle foram avaliadas amostras de 100 não-familiares. Anticorpos antimúsculo liso, antimitocondrial, anticélula gástrica parietal, antimicrosomal de fígado e rim e antimicrosomal tireoidiano foram testados por imunofluorescência indireta. *Resultados* - Foi observado um aumento significativo de positividade para os autoanticorpos em familiares de celíacos, quando comparados aos não-familiares ($P = 0,0064$), especificamente para o antimicrosomal tireoidiano e anticélula gástrica parietal. Entre os indivíduos com autoanticorpos positivos, a proporção do sexo feminino para o masculino foi de 4:1 e 3:1 em ambas as etapas ($P \leq 0,041$). A frequência de autoanticorpos detectada entre familiares de primeiro e segundo graus foi de 11,8% e 9,68% na etapa I e 4% e 6,67% na etapa II. *Conclusão* - Familiares de pacientes celíacos apresentam autoanticorpos positivos e o acompanhamento sorológico desses indivíduos é utilizado como instrumento na identificação de doenças autoimunes ao longo dos anos.

DESCRIPTORIOS – Autoanticorpos. Doença celíaca. Doenças autoimunes. Família.

REFERENCES

1. Almeida PL, Gandolfi L, Modelli IC, Martins R de C, Almeida RC, Pratesi R. Prevalence of celiac disease among first degree relatives of Brazilian celiac patients. *Arq Gastroenterol*. 2008;45:69-72.
2. Ansaldi N, Palmas T, Corrias A, Barbato M, D'Altiglia MR, Campanozzi A, Baldassarre M, Rea F, Pluvio R, Bonamico M, Lazzari R, Corrao G. Autoimmune thyroid disease and celiac disease in children. *J Pediatr Gastroenterol Nutr*. 2003;37:63-6.
3. Armstong MJ, Robins GG, Howdle PD. Recent advances in celiac disease. *Curr Opin Gastroenterol*. 2009;25:100-9.
4. Baptista ML, Koda YK, Mitsuneri R, Nisihara RM, Ioshii SO. Prevalence of celiac disease in Brazilian children and adolescents with type 1 diabetes mellitus. *J Pediatr Gastroenterol Nutr*. 2005; 41: 621-4.
5. Biagi F, Campanella J, Zanellati G. Incidence of celiac disease in first degree relatives [abstract]. In: XII International Celiac Disease Symposium, New York; 2006. poster D-259 p.86.
6. Biagi F, Corazza GR. First-degree relatives of celiac patients: are they at an increased risk of developing celiac disease? *J Clin Gastroenterol*. 2009;43:3-4.
7. Bigazzi PE, Rose NR. Pruebas para anticuerpos contra antígenos tisulares específicos. In: Rose NR, Friedman H, ed. *El laboratorio en inmunología clínica*. Buenos Aires: Pan Americana; 1984. p.968-79.
8. Bonaci-Nikolic B, Andrejevic S, Rodlovic N, Davidovic I, Sofronic L, Spuran M, Micev M, Nikolic MM. Serological and clinical comparison of children and adults with anti-endomysial antibodies. *J Clin Immunol*. 2007;27:163-71.
9. Bonamico M, Ferri M, Mariani P, Nenna R, Thanasi E, Luparia RP, Picarelli A, Magliocca FM, Mora B, Bardella MT, Verrienti A, Fiore B, Uccini S, Megiorni F, Mazzilli MC, Tiberti C. Serologic and genetic markers of celiac disease: a sequential study in the screening of first degree relatives. *J Pediatr Gastroenterol Nutr*. 2006;42:150-4.
10. da Rosa Utiyama SR, da Silva Kotze LM, Nisihara RM, Carvalho RF, de Carvalho EG, de Sena MG, de Messias Reason IJ. Spectrum of autoantibodies in celiac patients and relatives. *Dig Dis Sci*. 2001;46:2624-30.
11. da Rosa Utiyama SR, Nass FR, Kotze LM, Nisihara RM, Ambrosio AR, Messias-Reason IT. Serological screening of relatives of celiac disease patients: antiendomysium antibodies, anti tissue transglutaminase or both? *Arq Gastroenterol*. 2007;44:156-61.
12. da Rosa Utiyama SR. Doença celiaca: aspectos genéticos. In: Barbieri D, Kotze LMS, Rodrigues M, Romaldini CC, ed. *Atualização em doenças diarreicas da criança e do adolescente*. São Paulo, SP: Atheneu;2010:329-48.
13. Fernández A, González L, de-la-Fuente J. Coeliac disease: clinical features in adult populations. *Rev Esp Enferm Dig*. 2010;102:466-71.
14. Freeman HJ. Risk factors in familial forms of celiac disease. *World J Gastroenterol*. 2010;16:1828-31.
15. Gudjónsdóttir AH, Nilsson S, Ek J, Kristiansson B, Ascher H. The risk of celiac disease in 107 families with at least two affected siblings. *J Pediatr Gastroenterol Nutr*. 2004;38:338-42.
16. Hawkes ND, Swift GL, Smith PM, Jenkins HR. Incidence and presentation of coeliac disease in South Glamorgan. *Eur J Gastroenterol Hepatol* 2000;12:345-9.
17. Jones S, D'Souza C, Haboubi NY. Patterns of clinical presentation of adult coeliac disease in a rural setting. *Nutr J*. 2006;Sep 14;5:24.
18. Kotze LMS. Celiac disease in Brazilian patients: associations, complications and causes of death. Forty years of clinical experience. *Arq Gastroenterol* 2009;46:261-9.
19. Nass FR, Kotze LM, Nisihara RM, de Messias-Reason IJ, da Rosa Utiyama SR. Serological and clinical follow-up of relatives of celiac disease patients from Southern Brazil. *Digestion*. 2011;83:89-95.
20. Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. *Clin Exp Immunol*. 1973;15:331-44.
21. Rostom A, Murray JA, Kagnoff MF. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. *Gastroenterology*. 2006;131:1981-2002.
22. Sategna-Guidetti C, Soleiro E, Scaglione N, Aimo G, Mengozzi G. Duration of gluten exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders. *Gut*. 2001;49:502-5.
23. Sheehan NJ, Stanton-King K. Polyautoimmunity in a young woman. *Br J Rheumatol*. 1993;32:254-6.
24. Ventura A, Neri E, Ughi C, Leopaldi A, Città A, Not T. Gluten-dependent diabetes-related and thyroid-related autoantibodies in patients with celiac disease. *J Pediatr*. 2000;137:263-5.

Received 1/2/2012.
Accepted 11/5/2012.